[go: up one dir, main page]

NO20052828L - Polysakkaridvaksine for stafylokokkinfeksjoner - Google Patents

Polysakkaridvaksine for stafylokokkinfeksjoner

Info

Publication number
NO20052828L
NO20052828L NO20052828A NO20052828A NO20052828L NO 20052828 L NO20052828 L NO 20052828L NO 20052828 A NO20052828 A NO 20052828A NO 20052828 A NO20052828 A NO 20052828A NO 20052828 L NO20052828 L NO 20052828L
Authority
NO
Norway
Prior art keywords
dpnag
relates
staphylococci
polysaccharide vaccine
staphylococcal infections
Prior art date
Application number
NO20052828A
Other languages
English (en)
Other versions
NO20052828D0 (no
NO341730B1 (no
Inventor
Tomas Maira-Litran
Gerald B Pier
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO20052828D0 publication Critical patent/NO20052828D0/no
Publication of NO20052828L publication Critical patent/NO20052828L/no
Publication of NO341730B1 publication Critical patent/NO341730B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Oppfinnelsen vedrører sammensetninger av et deacetylert poly-N-acetylert glukosamin (dPNAG) av stafylokokker. dPNAG kan isoleres fra naturlig kilder eller syntetiseres de novo. Oppfinnelsen vedrører også anvendelsen av dPNAG som en vaksine for å indusere aktiv immunitet mot infeksjon bevirket ved Stap.hypococcus aureus,' S. epidemidis, andre relaterte koagulase-negative eller koagulase-positive stafylokokker, og andre organismer som bærer ica (intracellulær adhesjon) locuset. Oppfinnelsen tilveiebringer videre fremgangsmåter for anvendelse av antistoffer rettet mot dPNAG, særlig for å indusere passiv immunitet mot den samme klassen av infeksjoner.
NO20052828A 2002-11-12 2005-06-10 Sammensetning omfattende et isolert polysakkarid, fremgangsmåte for fremstilling av polysakkaridet og farmasøytisk sammensetning omfattende dette NO341730B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42542502P 2002-11-12 2002-11-12
PCT/US2003/036358 WO2004043405A2 (en) 2002-11-12 2003-11-12 Polysaccharide vaccine for staphylococcal infections

Publications (3)

Publication Number Publication Date
NO20052828D0 NO20052828D0 (no) 2005-06-10
NO20052828L true NO20052828L (no) 2005-08-12
NO341730B1 NO341730B1 (no) 2018-01-15

Family

ID=32312989

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052828A NO341730B1 (no) 2002-11-12 2005-06-10 Sammensetning omfattende et isolert polysakkarid, fremgangsmåte for fremstilling av polysakkaridet og farmasøytisk sammensetning omfattende dette

Country Status (18)

Country Link
US (1) US10919956B2 (no)
EP (1) EP1565478B1 (no)
JP (5) JP5814494B2 (no)
KR (1) KR101062525B1 (no)
CN (1) CN100351260C (no)
AU (1) AU2003295520B8 (no)
BR (1) BRPI0316018B8 (no)
CA (1) CA2501077C (no)
DK (1) DK1565478T3 (no)
ES (1) ES2648046T3 (no)
IL (3) IL167532A (no)
MX (1) MXPA05005045A (no)
NO (1) NO341730B1 (no)
NZ (1) NZ539153A (no)
PL (1) PL229487B1 (no)
PT (1) PT1565478T (no)
WO (1) WO2004043405A2 (no)
ZA (1) ZA200502607B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
PT1565478T (pt) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
US20080085289A1 (en) * 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
JP2008517918A (ja) 2004-10-21 2008-05-29 ワイス Ｓｔａｐｈｙｌｏｃｏｃｃｕｓｅｐｉｄｅｒｍｉｄｉｓポリペプチド抗原の免疫原性組成物
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
MX2008014978A (es) 2006-06-06 2008-12-09 Crucell Holland Bv Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
SI2395018T1 (sl) 2006-06-06 2016-06-30 Crucell Holland B.V. Humane vezne molekule, z ubijalsko aktivnostjo proti stafilokokom in njihova uporaba
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
RS56000B1 (sr) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
HUE052610T2 (hu) 2010-03-17 2021-05-28 Socpra Sciences Et Genie Sec Bakteriális vakcina komponensek Staphylococcus aureusból és alkalmazásaik
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
EP2844275B1 (en) 2012-04-26 2020-05-13 University of Chicago Staphylococcal coagulase antigens and methods of their use
US20150147328A1 (en) * 2012-05-07 2015-05-28 Mogam Biotechnology Institute Vaccine composition for preventing staphyllococcus aureus infection
KR102282726B1 (ko) * 2012-05-30 2021-07-29 더 브리검 앤드 우먼즈 하스피털, 인크. 폴리사카라이드 조성물 및 사용 방법
JP2017518373A (ja) * 2014-05-29 2017-07-06 グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． スタフィロコッカス・アウレウス感染疾患の予防または治療用組成物
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물
KR101847051B1 (ko) 2016-04-26 2018-04-09 한국외국어대학교 연구산학협력단 병원균에 대한 항생활성을 갖는 펩타이드 및 이를 포함하는 항생 펩타이드 조성물
PE20191320A1 (es) 2016-10-21 2019-09-24 Socpra Sciences Et Genie Sec Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US20200355139A1 (en) 2019-05-10 2020-11-12 Mazda Motor Corporation Engine piston and method for manufacturing the same
WO2021041721A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
US10828360B1 (en) 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2842049A (en) * 1954-09-22 1958-07-08 Technicolor Corp Deacetylated chitin mordant
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4285936A (en) 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4443549A (en) 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4465776A (en) * 1982-09-27 1984-08-14 Research Corporation Monoclonal antibodies to vitamin B6 and immunoassay method
US4652448A (en) 1982-10-07 1987-03-24 Molecular Genetics, Inc. Use of monoclonal antibodies against bacterial adhesins
US4578458A (en) 1983-03-23 1986-03-25 Brigham And Women's Hospital Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
US4786592A (en) 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8621910D0 (en) 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
FR2640628A1 (fr) 1988-12-16 1990-06-22 Commissariat Energie Atomique Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
CA2039789A1 (en) 1990-04-27 1991-10-28 Samuel J. Danishefsky Calicheamicinone, derivatives and analogs thereof and methods of making the same
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5763191A (en) * 1990-12-12 1998-06-09 Boehringer Mannheim Gmbh Universal binding film
DE4219159A1 (de) 1992-06-11 1993-12-16 Boehringer Mannheim Gmbh Selbst assemblierende Monoschicht mit kurzkettigen Linkern
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
JP3129441B2 (ja) 1991-07-12 2001-01-29 ファイザー・インコーポレイテッド トリ・コクシジウムに対する継代細胞系およびワクチン
CA2123811C (en) 1991-11-22 2005-07-05 Ali Ibrahim Fattom Type i and type ii surface antigens associated with staphylococcus epidermidis
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
JPH07505131A (ja) 1991-12-06 1995-06-08 ノース・ショアー・ユニバーシティー・ホスピタル・リサーチ・コーポレーション 医療装置関連感染の減少方法
WO1993019373A1 (en) 1992-03-19 1993-09-30 U.S. GOVERNMENT, as represented by THE SECRETARY O Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
CA2153661A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5718694A (en) 1993-11-09 1998-02-17 The Board Of Regents Of The University Of Nebraska Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
MX9504802A (es) 1994-03-17 1997-05-31 Merck Patent Gmbh Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
WO1997017334A1 (fr) 1995-11-06 1997-05-15 Chugai Seiyaku Kabushiki Kaisha Derives d'imine de sydnone
US5830539A (en) 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
WO1997019105A1 (en) 1995-11-21 1997-05-29 Novartis Ag Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds.
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6903194B1 (en) * 1996-09-26 2005-06-07 Chungai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
AU733282B2 (en) 1997-04-18 2001-05-10 Novartis Ag Neoglycoproteins
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
TW586934B (en) 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US5989542A (en) 1997-08-20 1999-11-23 Brigham And Women's Hospital, Inc. Capsular polysaccharides from enterococci
IT1298539B1 (it) 1998-02-03 2000-01-12 Bracco Spa Metodo per la determinazione di infezioni da protesi
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
CA2319089A1 (en) 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
ES2308844T3 (es) 1998-07-15 2008-12-01 The Brigham And Women's Hospital, Inc. Vacuna de polisacaridos para infecciones estafilococidas.
CA2341018C (en) * 1998-08-31 2012-07-31 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
SK7982001A3 (en) 1998-12-16 2002-02-05 Sca Hygiene Prod Zeist Bv Acidic superabsorbent polysaccharides
SI1163000T1 (sl) 1999-03-19 2008-06-30 Glaxosmithkline Biolog Sa Vakcina proti antigenom iz bakterij
AU2002309567A1 (en) 2001-05-16 2002-12-03 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
AU2002303832A1 (en) 2001-05-21 2002-12-03 Beth Israel Deaconess Medical Center, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
CN1344722A (zh) 2001-10-19 2002-04-17 北京盈富安信科技有限公司 1→6连接的氨基葡聚寡糖和糖苷及其合成和应用
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
JP2005532415A (ja) * 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
JP2005514425A (ja) * 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
PT1565478T (pt) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
DE602004017864D1 (de) 2003-06-23 2009-01-02 Baxter Int Trägerproteine für impfstoffe
US9928522B2 (en) 2003-08-01 2018-03-27 Oath (Americas) Inc. Audience matching network with performance factoring and revenue allocation
DE602004009314T2 (de) 2003-08-12 2008-02-07 Lipoxen Technologies Ltd. Polysialinsäurederivate
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
CA2475736A1 (en) 2004-07-23 2006-01-23 Cyrille Grandjean Vibrio cholerae lps detoxified derivatives and immunogenic compositions containing them
US20080085289A1 (en) 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
CA2600696A1 (en) 2005-03-14 2006-09-21 Governors Of The University Of Alberta Synthetic anti-candida albicans oligosaccharide based vaccines
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
EP2399595B1 (en) * 2009-02-20 2015-11-04 Meisho.Co., Ltd Immunopotentiating composition and process for producing same
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
KR102282726B1 (ko) * 2012-05-30 2021-07-29 더 브리검 앤드 우먼즈 하스피털, 인크. 폴리사카라이드 조성물 및 사용 방법
EP3608416A1 (en) 2013-01-22 2020-02-12 Imicroq, S.L. Rapid method for detection of pathogen

Also Published As

Publication number Publication date
BR0316018A (pt) 2005-09-20
PL229487B1 (pl) 2018-07-31
BRPI0316018B8 (pt) 2021-05-25
EP1565478A2 (en) 2005-08-24
AU2003295520B8 (en) 2011-05-19
WO2004043405A3 (en) 2004-10-21
WO2004043405A2 (en) 2004-05-27
AU2003295520B2 (en) 2011-04-14
IL263585A (en) 2019-01-31
ZA200502607B (en) 2006-07-26
JP6335102B2 (ja) 2018-05-30
US20050118198A1 (en) 2005-06-02
KR20050074582A (ko) 2005-07-18
JP2006513166A (ja) 2006-04-20
BRPI0316018B1 (pt) 2017-04-04
JP2016204388A (ja) 2016-12-08
CA2501077C (en) 2016-06-21
CN100351260C (zh) 2007-11-28
NZ539153A (en) 2006-11-30
NO20052828D0 (no) 2005-06-10
MXPA05005045A (es) 2005-07-01
US10919956B2 (en) 2021-02-16
JP5814494B2 (ja) 2015-11-17
AU2003295520A1 (en) 2004-06-03
CN1708506A (zh) 2005-12-14
JP2015042676A (ja) 2015-03-05
EP1565478B1 (en) 2017-08-02
JP2019089845A (ja) 2019-06-13
ES2648046T3 (es) 2017-12-28
WO2004043405A8 (en) 2004-08-05
DK1565478T3 (da) 2017-11-13
PT1565478T (pt) 2017-11-14
PL377145A1 (pl) 2006-01-23
EP1565478A4 (en) 2007-01-03
CA2501077A1 (en) 2004-05-27
IL167532A (en) 2014-12-31
NO341730B1 (no) 2018-01-15
IL209149A0 (en) 2011-01-31
JP2013010789A (ja) 2013-01-17
KR101062525B1 (ko) 2011-09-06

Similar Documents

Publication Publication Date Title
NO20052828L (no) Polysakkaridvaksine for stafylokokkinfeksjoner
CY1108542T1 (el) Εμβολιο πολυσακχαριτη για μολυνσεις απο σταφυλοκοκκο
DK1162997T3 (da) Staphylococcus-antigen og -vaccine
DE60230670D1 (de) Staphylococcus aureus exopolysaccharid und verfahren
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
AU2001278003A1 (en) Bacteriophage having multiple host range
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
HUP0400446A2 (hu) Azitromicin kristályformái
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
EA200801839A1 (ru) Иммуногенная композиция
WO2003010138A3 (en) Piperidine derivatives as antibacterial agents
JP2006502129A5 (no)
WO2007053176A3 (en) Method of protecting against staphylococcal infection
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
NO20044548L (no) Fremgangsmate for fremstilling av 6-alkaliden-penemderivater
WO2002094190A3 (en) Heterologous protection induced by immunization with invaplex vaccine
EA200801856A1 (ru) Система привода для манипулятора (варианты)
NO20010140L (no) Kjemotakse-inhiberende protein av Staphylococcus (CHIPS) og dets anvendelse
PE20070825A1 (es) Nuevo derivado de pleuromutilina y su uso
EP1550705A4 (en) ALLERGEN INACTIVATOR
WO2008044149A8 (en) Shigella ipad protein and its use as a vaccine against shigella infection
WO2007136763A3 (en) Immunological composition
NO20075195L (no) En fremgangsmate for rensingen av 10-deacetylbaccatin III fra 10-deacetyl-2-deabenzoyl-2-pentenoylbaccatin III
UY29012A1 (es) "oxazolididonas y composiciones y metodos relacionados"
BR112022002094A2 (pt) Composição imunogênica

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees